Cargando…
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia
BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199623/ https://www.ncbi.nlm.nih.gov/pubmed/16042797 http://dx.doi.org/10.1186/1465-9921-6-82 |
_version_ | 1782124882616647680 |
---|---|
author | Mortensen, Eric M Restrepo, Marcos I Anzueto, Antonio Pugh, Jacqueline |
author_facet | Mortensen, Eric M Restrepo, Marcos I Anzueto, Antonio Pugh, Jacqueline |
author_sort | Mortensen, Eric M |
collection | PubMed |
description | BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. RESULTS: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased 30-day mortality. DISCUSSION: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect. |
format | Text |
id | pubmed-1199623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11996232005-09-09 The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia Mortensen, Eric M Restrepo, Marcos I Anzueto, Antonio Pugh, Jacqueline Respir Res Research BACKGROUND: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia. METHODS: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation. RESULTS: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased 30-day mortality. DISCUSSION: Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect. BioMed Central 2005 2005-07-25 /pmc/articles/PMC1199623/ /pubmed/16042797 http://dx.doi.org/10.1186/1465-9921-6-82 Text en Copyright © 2005 Mortensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Mortensen, Eric M Restrepo, Marcos I Anzueto, Antonio Pugh, Jacqueline The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title | The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title_full | The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title_fullStr | The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title_full_unstemmed | The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title_short | The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
title_sort | effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199623/ https://www.ncbi.nlm.nih.gov/pubmed/16042797 http://dx.doi.org/10.1186/1465-9921-6-82 |
work_keys_str_mv | AT mortensenericm theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT restrepomarcosi theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT anzuetoantonio theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT pughjacqueline theeffectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT mortensenericm effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT restrepomarcosi effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT anzuetoantonio effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia AT pughjacqueline effectofpriorstatinuseon30daymortalityforpatientshospitalizedwithcommunityacquiredpneumonia |